COMPARATIVE STUDY OF TIMOPTOL-XE® VERSUS TIMOPTOL® IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Chao-Yu Hu, Lin-Chung Woung,
Jeen-Hon Jian

Topical beta-blockers are widely used anti-glaucoma drugs, and usually they are considered the first line drug for various types of glaucoma. Decrease the frequency of instillation without damping the drug effect is a good idea for most of the glaucoma patients who almost need to take these medicines for life. So we decided to perform this clinical trial to evaluate the responses of the topical beta-blocker that was used once a day. Of course, the responses we had concened included favored (reduction of intraocular pressure) and disfavored (bradycardia, hypotension).

A 12-week, randomized, open-labeled, two-period cross-over (6 weeks each period) study was designed; 40 subjects with ocular hypertension, primary open-angle glaucoma, or chronic angle-closure glaucoma were included and treated topically with either timolol maleate 0.5% in Gelrite (Timoptol-XE®) once a day or aqueous timolol maleate 0.5% (Timoptol®) twice a day in a random order of drug use for each 6-week period. There was no statistically significant difference in intraocular pressure, blood pressure, and heart rate between these different groups of treatment; neither is in the different sequence and phases. There was also no difference in adverse effects and preference between these two formulations.

Received: April 6, 1998, Revised: May 5, 1998, Accepted: May 12, 1998.
Department of Ophthalmology, Taipei Municipal Yang-Ming Hospital.
Correspondence and reprint requests to: Lin-Chung Woung, Department of Ophthalmology, Taipei Municipal Yang-Ming Hospital, 105, Yu-Sheng St., Shih-Lin, Taipei, Taiwan.